Published in J Clin Invest on March 23, 2009
WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer (2013) 6.64
Osteoporosis: now and the future. Lancet (2011) 5.81
WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med (2013) 4.52
Update on Wnt signaling in bone cell biology and bone disease. Gene (2011) 2.03
Secreted and transmembrane wnt inhibitors and activators. Cold Spring Harb Perspect Biol (2013) 2.01
Severe polyposis in Apc(1322T) mice is associated with submaximal Wnt signalling and increased expression of the stem cell marker Lgr5. Gut (2010) 1.84
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
Sclerostin: current knowledge and future perspectives. Calcif Tissue Int (2010) 1.71
Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis (2011) 1.68
Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene (2011) 1.66
Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab (2012) 1.54
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet (2010) 1.44
Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma. Mol Cancer Ther (2010) 1.37
Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Invest (2010) 1.35
The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging. J Steroid Biochem Mol Biol (2010) 1.34
Promising bone-related therapeutic targets for rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.25
Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis (2013) 1.25
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches. Nat Rev Endocrinol (2013) 1.23
Wnt modulators in the biotech pipeline. Dev Dyn (2010) 1.23
Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum (2012) 1.22
High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. Cancer Cell (2011) 1.22
Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface. Cancer Res (2010) 1.21
Modular mechanism of Wnt signaling inhibition by Wnt inhibitory factor 1. Nat Struct Mol Biol (2011) 1.21
Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun (2013) 1.18
Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/β-catenin antagonists against human osteosarcoma cells. Invest New Drugs (2010) 1.11
Growth factor control of bone mass. J Cell Biochem (2009) 1.07
Treatment of osteoporosis in men. Bone (2012) 1.06
Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab (2010) 1.03
MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem (2013) 1.01
Notch activation as a driver of osteogenic sarcoma. Cancer Cell (2014) 0.99
A systems biology approach reveals common metastatic pathways in osteosarcoma. BMC Syst Biol (2012) 0.99
High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes. Bone Res (2014) 0.98
Perspectives on cancer stem cells in osteosarcoma. Cancer Lett (2012) 0.97
Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. Genes Dis (2016) 0.97
Wnt inhibitory factor 1 (Wif1) is regulated by androgens and enhances androgen-dependent prostate development. Endocrinology (2012) 0.96
Wnt10b activates the Wnt, notch, and NFκB pathways in U2OS osteosarcoma cells. J Cell Biochem (2011) 0.96
Impaired cell cycle regulation of the osteoblast-related heterodimeric transcription factor Runx2-Cbfbeta in osteosarcoma cells. J Cell Physiol (2009) 0.95
Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer (2013) 0.95
Role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases. Ther Adv Musculoskelet Dis (2014) 0.94
Osteosarcomagenesis: modeling cancer initiation in the mouse. Sarcoma (2011) 0.94
Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. J Clin Invest (2013) 0.92
An unexpected role for a Wnt-inhibitor: Dickkopf-1 triggers a novel cancer survival mechanism through modulation of aldehyde-dehydrogenase-1 activity. Cell Death Dis (2014) 0.92
The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab Invest (2015) 0.91
Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn (2011) 0.91
FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo. PLoS One (2013) 0.91
Trps1 activates a network of secreted Wnt inhibitors and transcription factors crucial to vibrissa follicle morphogenesis. Development (2011) 0.90
The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma. Biomed Res Int (2013) 0.90
Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone. Br J Cancer (2010) 0.88
Regulation of breast cancer-induced bone lesions by β-catenin protein signaling. J Biol Chem (2011) 0.88
Characterization of β-catenin expression in canine osteosarcoma. Vet Comp Oncol (2011) 0.87
Separate and combined effects of DNMT and HDAC inhibitors in treating human multi-drug resistant osteosarcoma HosDXR150 cell line. PLoS One (2014) 0.87
Beyond oncology--application of HPMA copolymers in non-cancerous diseases. Adv Drug Deliv Rev (2009) 0.86
Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence. Cell Death Dis (2014) 0.86
Immunohistochemical investigation of cell cycle and apoptosis regulators (survivin, β-catenin, p53, caspase 3) in canine appendicular osteosarcoma. BMC Vet Res (2012) 0.85
Aberrant activation of Wnt/β-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget (2015) 0.85
Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma. PLoS One (2014) 0.84
The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Med (2013) 0.83
The role of glypicans in Wnt inhibitory factor-1 activity and the structural basis of Wif1's effects on Wnt and Hedgehog signaling. PLoS Genet (2012) 0.83
The genetic basis for inactivation of Wnt pathway in human osteosarcoma. BMC Cancer (2014) 0.81
Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Crit Rev Oncog (2015) 0.81
Dysregulation of Wnt inhibitory factor 1 (Wif1) expression resulted in aberrant Wnt-β-catenin signaling and cell death of the cloaca endoderm, and anorectal malformations. Cell Death Differ (2014) 0.81
The Drosophila WIF1 homolog Shifted maintains glypican-independent Hedgehog signaling and interacts with the Hedgehog co-receptors Ihog and Boi. Development (2012) 0.80
New treatment modalities in osteoporosis. Endocr Pract (2011) 0.80
Wnt therapy for bone loss: golden goose or Trojan horse? J Clin Invest (2009) 0.80
A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget (2016) 0.79
Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data. Hum Genomics (2014) 0.79
Osteoimmunology: Wnt antagonists: for better or worse? Nat Rev Rheumatol (2009) 0.79
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma (2013) 0.78
ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells. BMC Biol (2010) 0.78
Aberrant CXCR4 and β-catenin expression in osteosarcoma correlates with patient survival. Oncol Lett (2015) 0.76
β-Catenin Does Not Confer Tumorigenicity When Introduced into Partially Transformed Human Mesenchymal Stem Cells. Sarcoma (2012) 0.76
Imprinting defects at human 14q32 locus alters gene expression and is associated with the pathobiology of osteosarcoma. Oncotarget (2016) 0.76
Rac1 modulates mammalian lung branching morphogenesis in part through canonical Wnt signaling. Am J Physiol Lung Cell Mol Physiol (2016) 0.75
High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation through the β-Catenin/Wnt Signaling Pathway and Is Associated with Poor Prognosis. Int J Mol Sci (2016) 0.75
Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma. Sci Rep (2017) 0.75
Induction of WNT inhibitory factor 1 expression by Müllerian inhibiting substance/antiMullerian hormone in the Müllerian duct mesenchyme is linked to Müllerian duct regression. Dev Biol (2013) 0.75
Effects of fulvestrant on biological activity and Wnt expression in rat GH3 cells. Neural Regen Res (2012) 0.75
Genetic polymorphism in extracellular regulators of Wnt signaling pathway. Biomed Res Int (2015) 0.75
Hedgehog/Patched-associated rhabdomyosarcoma formation from delta1-expressing mesodermal cells. Oncogene (2015) 0.75
The Protein Tyrosine Phosphatase Rptpζ Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice. PLoS One (2015) 0.75
Deciphering signaling networks in osteosarcoma pathobiology. Exp Biol Med (Maywood) (2016) 0.75
Molecular genetics of osteosarcoma. Bone (2016) 0.75
Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors. Curr Osteoporos Rep (2017) 0.75
Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res (2002) 40.03
A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A (1992) 29.51
Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature (1999) 20.34
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc Natl Acad Sci U S A (1993) 20.33
Improved retroviral vectors for gene transfer and expression. Biotechniques (1989) 19.48
LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell (2001) 11.99
High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med (2002) 11.28
Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc Natl Acad Sci U S A (2005) 8.10
Secreted antagonists of the Wnt signalling pathway. J Cell Sci (2003) 8.02
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci U S A (1975) 7.27
DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet (2000) 6.57
The many ways of Wnt in cancer. Curr Opin Genet Dev (2007) 6.29
Sp1 elements protect a CpG island from de novo methylation. Nature (1994) 5.60
Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene (2006) 5.12
Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood (1991) 4.49
Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology (2007) 3.46
Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res (2006) 3.44
Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology (2005) 3.42
Mechanisms of anabolic therapies for osteoporosis. N Engl J Med (2007) 3.33
A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature (1999) 3.22
Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev (1998) 3.01
DNA methylation represses transcription in vivo. Nat Genet (1999) 2.92
Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev (2004) 2.75
Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene (2006) 2.69
Molecular pathogenesis of osteosarcoma. DNA Cell Biol (2007) 2.31
Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem (1997) 2.27
The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res (2004) 2.16
Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol Pathol (2006) 2.12
Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat Genet (2005) 2.10
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 2.09
Allele-specific expression and total expression levels of imprinted genes during early mouse development: implications for imprinting mechanisms. Genes Dev (1995) 2.03
Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol (2004) 1.88
Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene (2005) 1.82
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet (2003) 1.77
Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway. Clin Cancer Res (2006) 1.73
Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J Bone Miner Res (1999) 1.73
An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res (2005) 1.60
CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene (1998) 1.58
Lymphoid enhancer factor-1 and beta-catenin inhibit Runx2-dependent transcriptional activation of the osteocalcin promoter. J Biol Chem (2003) 1.57
Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest (2000) 1.54
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol (2004) 1.52
Retracted Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. Blood (2006) 1.49
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis (2006) 1.47
Roles of Wnt signalling in bone growth, remodelling, skeletal disorders and fracture repair. J Cell Physiol (2008) 1.47
Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer (2002) 1.37
Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26
In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One (2008) 1.24
The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology (2007) 1.21
Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis (2003) 1.19
Comprehensive microarray analysis of bone morphogenetic protein 2-induced osteoblast differentiation resulting in the identification of novel markers for bone development. J Bone Miner Res (2002) 1.19
Osteosarcoma and teriparatide? J Bone Miner Res (2007) 1.14
Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology (2007) 1.07
Epigenetic modifications in osteogenic differentiation and transformation. J Cell Biochem (2006) 1.06
Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J Cell Physiol (2007) 1.06
Functional analysis of CpG methylation in the BRCA1 promoter region. Oncogene (2001) 1.06
Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology (1995) 1.05
Perinatal testosterone surge is required for normal adult bone size but not for normal bone remodeling. Am J Physiol Endocrinol Metab (2005) 1.03
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res (2005) 1.02
Clinical relevance of Ki-67 expression in bone tumors. Cancer (1995) 1.00
Identification of genes differentially expressed by prematurely fused human sutures using a novel in vivo - in vitro approach. Differentiation (2007) 0.98
Frequent beta-catenin abnormalities in bone and soft-tissue tumors. Jpn J Cancer Res (1999) 0.93
In situ histochemical detection of beta-galactosidase activity in lung: assessment of X-Gal reagent in distinguishing lacZ gene expression and endogenous beta-galactosidase activity. Hum Gene Ther (1997) 0.91
WIF1, an inhibitor of the Wnt pathway, is rearranged in salivary gland tumors. Genes Chromosomes Cancer (2007) 0.88
Sex and tissue-specific differences in low-dose radiation-induced oncogenic signaling. Int J Radiat Biol (2005) 0.85
PARAMETERS OF RADIATION DOSAGE THAT INFLUENCE PRODUCTION OF OSTEOGENIC SARCOMAS IN MICE. Natl Cancer Inst Monogr (1964) 0.81
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Oct4-induced pluripotency in adult neural stem cells. Cell (2009) 6.50
Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell (2008) 6.26
The Hippo pathway and human cancer. Nat Rev Cancer (2013) 5.17
DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med (2011) 4.98
The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine. Nat Med (2013) 4.32
Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood (2005) 4.17
Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci (2003) 4.10
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell (2007) 3.82
G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood (2005) 3.76
Empirical array quality weights in the analysis of microarray data. BMC Bioinformatics (2006) 3.54
Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest (2003) 3.52
Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation. Genes Dev (2003) 3.46
Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med (2012) 3.39
Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood (2010) 3.26
DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med (2012) 3.18
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer (2006) 2.97
Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med (2005) 2.72
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res (2007) 2.69
Efficient targeted gene disruption in Xenopus embryos using engineered transcription activator-like effector nucleases (TALENs). Proc Natl Acad Sci U S A (2012) 2.53
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res (2012) 2.46
Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev (2007) 2.34
Molecular pathogenesis of osteosarcoma. DNA Cell Biol (2007) 2.31
Murine dishevelled 3 functions in redundant pathways with dishevelled 1 and 2 in normal cardiac outflow tract, cochlea, and neural tube development. PLoS Genet (2008) 2.29
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med (2012) 2.19
Osteosarcoma treatment: state of the art. Cancer Metastasis Rev (2009) 2.19
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer (2008) 2.16
Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int (2010) 2.12
Automated image-based phenotypic analysis in zebrafish embryos. Dev Dyn (2009) 2.11
Control of vertebrate multiciliogenesis by miR-449 through direct repression of the Delta/Notch pathway. Nat Cell Biol (2011) 2.09
Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res (Phila) (2010) 2.08
A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol (2007) 2.07
Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology (2010) 2.02
Neural induction in Xenopus requires early FGF signalling in addition to BMP inhibition. Development (2004) 2.01
Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood (2004) 2.01
The osteochondral dilemma: review of current management and future trends. ANZ J Surg (2013) 2.00
Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. Cancer Res (2008) 1.99
EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res (2008) 1.97
A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells. Stem Cells Dev (2007) 1.96
Erythropoietin couples erythropoiesis, B-lymphopoiesis, and bone homeostasis within the bone marrow microenvironment. Blood (2011) 1.96
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol (2012) 1.95
Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. Sci STKE (2004) 1.93
SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest (2006) 1.92
Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice. J Cell Biol (2007) 1.92
The molecular pathogenesis of osteosarcoma: a review. Sarcoma (2011) 1.91
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 1.88
Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol (2004) 1.88
Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol (2009) 1.88
Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res (2011) 1.87
Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. Exp Hematol (2012) 1.85
The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood (2007) 1.84
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 1.83
Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol (2002) 1.82
Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood (2007) 1.81
Methylation-sensitive high-resolution melting. Nat Protoc (2008) 1.80
Detection of MGMT promoter methylation in normal individuals is strongly associated with the T allele of the rs16906252 MGMT promoter single nucleotide polymorphism. Cancer Prev Res (Phila) (2009) 1.78
White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res (2009) 1.78
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn (2009) 1.76
Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol (2002) 1.75
Specialized and redundant roles of TBP and a vertebrate-specific TBP paralog in embryonic gene regulation in Xenopus. Proc Natl Acad Sci U S A (2004) 1.74
Generation of FGF reporter transgenic zebrafish and their utility in chemical screens. BMC Dev Biol (2007) 1.74
Endogenous fibroblastic progenitor cells in the adult mouse lung are highly enriched in the sca-1 positive cell fraction. Stem Cells (2009) 1.74
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys (2003) 1.73
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget (2012) 1.69
High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer (2007) 1.65
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
General transcription factor binding at CpG islands in normal cells correlates with resistance to de novo DNA methylation in cancer cells. Cancer Res (2010) 1.64
Obesity is a major risk factor for prosthetic infection after primary hip arthroplasty. Clin Orthop Relat Res (2008) 1.64
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A (2009) 1.63
Lipid lowering efficacy of atorvastatin. Cochrane Database Syst Rev (2012) 1.62
Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem (2013) 1.62
Early outcomes and complications following joint arthroplasty in obese patients: a review of the published reports. ANZ J Surg (2008) 1.60
Defining the risks of mesenchymal stromal cell therapy. Cytotherapy (2010) 1.60
RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev (2007) 1.57
Sensitive Melting Analysis after Real Time- Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res (2008) 1.57
Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Mol Cancer Ther (2009) 1.56
EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone. J Bone Miner Res (2013) 1.55
Liposarcoma: molecular genetics and therapeutics. Sarcoma (2010) 1.55
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res (2013) 1.54
Distinct roles for Fgf, Wnt and retinoic acid in posteriorizing the neural ectoderm. Development (2002) 1.54
A role for MKP3 in axial patterning of the zebrafish embryo. Development (2004) 1.54
Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics (2014) 1.53
Mesenchymal stem cells. Arch Med Res (2004) 1.53
GLUT10 is required for the development of the cardiovascular system and the notochord and connects mitochondrial function to TGFβ signaling. Hum Mol Genet (2011) 1.52
Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood (2009) 1.50
Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther (2008) 1.48
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res (2010) 1.48
Obese diabetic patients are at substantial risk for deep infection after primary TKA. Clin Orthop Relat Res (2008) 1.46
The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line. Cancer Res (2005) 1.45
The implications of heterogeneous DNA methylation for the accurate quantification of methylation. Epigenomics (2010) 1.45
Quantification of fetal DNA by use of methylation-based DNA discrimination. Clin Chem (2010) 1.45
Model structure and control of bone remodeling: a theoretical study. Bone (2008) 1.44
The zebrafish van gogh mutation disrupts tbx1, which is involved in the DiGeorge deletion syndrome in humans. Development (2003) 1.43
Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum (2006) 1.42
A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes (2008) 1.42